Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-il-1r3 antibodies for use in inflammatory conditions

A technology for inflammatory diseases and inflammatory diseases, applied in the field of anti-IL-1R3 antibodies for inflammatory diseases, can solve problems such as hindering therapeutic use

Pending Publication Date: 2020-02-21
SANOFI BIOTECH SAS
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Unfortunately, existing IL-1 pathway inhibitors such as Kineret, ilaris or Arcalyst have certain disadvantages that hinder their therapeutic use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-il-1r3 antibodies for use in inflammatory conditions
  • Anti-il-1r3 antibodies for use in inflammatory conditions
  • Anti-il-1r3 antibodies for use in inflammatory conditions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0188] Example 1: Human IL-1R3 biochemical ELISA

[0189] Analysis principle:

[0190] The NUNC Maxisorp 384-well microtiter plate was coated with Fc-tagged human IL-1R3. After the blocking process, the specific antibody from the B cell supernatant binds to the antigen and is subsequently detected with POD-labeled antibody. The sample is tested at 1:2 dilution.

[0191] material:

[0192] Plate: 384-well NUNC Maxisorp plate; catalog number 464718

[0193] Protein: Fc-tagged human IL-1R3 (concentration 1.5mg / ml; analysis concentration 0.5μg / mL)

[0194] Standard Ab: P013-02 (concentration 1mg / ml; initial analysis concentration 2μg / mL)

[0195] Detection Ab: anti-rabbit IgG, peroxidase-linked species-specific complete antibody (from donkey) (ECL); GE; catalog number NA9340; analytical dilution: 1:5000

[0196] PBS: buffer in the box, premixed PBS buffer, 10x; Roche Applied Sciences; catalog number 11666789001

[0197] BSA: Bovine Serum Albumin Fraction V from Bovine Serum; Roche Applied Sci...

Embodiment 2

[0216] Example 2: Characterization of h-IL-1R3 specific antibody that inhibits h-IL-1R3-receptor by luciferase reporter experiment

[0217] Analysis principle:

[0218] Inoculate poly-D-lysine-cell culture plates with 293T / 17-FR cells expressing NF-kB-RE firefly luciferase reporter molecule. After IL-1b stimulation, the 293T / 17-FR lysate was tested for activated NF-kB using Steady-Glo Luciferase Assay Kit. The supernatant containing functional antibodies binds to hIL-1R3 and inhibits NF-kB activation, which is shown by a low signal.

[0219] material:

[0220] Plate: Cell plate: 384-well PDL Costar cell culture plate; catalog number 3844

[0221] Analysis plate: 384-well lumitrac white-plate; Corning; catalog number 3572

[0222] Cells: 293T / 17-FR; analysis concentration 250,000 cells / ml

[0223] Protein: IL-1b (concentration 0.03mg / ml; analytical concentration 115pg / ml; working concentration 230pg / ml)

[0224] Standard Ab: P013_06 (concentration 0.2mg / ml; initial working concentration 6...

Embodiment 3

[0238] Example 3: Inhibition of NFκB expression in A549-NFκB-RE-Luc stably transfected cells after IL-1 (α / β) stimulation

[0239] Analysis principle:

[0240] A549-NFκB-RE-Luc stably transfected cells (Signosis) were aspirated into a 384-well plate and incubated overnight. On the second day, the cells stably transfected with the anti-IL1R3 antibody and bound A549-NFkB-RE-Luc were allowed, and then these cells were stimulated by adding IL-1 (α or β). This leads to the transcription of the luciferase gene due to the activation of the NFκB signaling pathway and can be measured by lysing the cells and adding luciferin.

[0241] Test whether the antibody can inhibit the activation of the NFkB pathway and thus reduce the luminescence signal.

[0242] material:

[0243] Plate: Sterile 384-well low-side white flat-bottomed polystyrene TC-treated microplate; Corning; catalog number 3570

[0244] Protein: IL-1α (P026_09); Recombinant human IL-1α / IL-1F1; 10μg / mL; R&D Systems; Catalog number 200-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to methods for treating medical conditions and / or disorders characterized by uncontrolled or abnormal expression of members of the IL1R3 signaling pathway such as IL-lalpha, IL-Ibeta, IL-33, IL-36, IL1RA and / or IL1R3, as well as variants thereof. More specifically, the present invention relates to anti-IL1R3 antibodies for use in the treatment of an ILlR3-mediated inflammatory condition and / or disorder in a subject. Such conditions and disorders include but are not limited to inflammatory diseases, immune disorders, fibrotic disorders, eosinophilic disorders, infection, pain, a central nervous system disorder, an ophthalmologic disorder, Hereditary Systemic Inflammatory Diseases, and Systemic and Local Inflammatory Diseases and cancer associated chronic inflammation.

Description

Technical field [0001] The present invention relates to a method for treating medical conditions and / or diseases characterized by uncontrolled or abnormal expression of IL1R3 signaling pathway members such as IL-1α, IL-1β, IL-33, IL-36, IL1RA, and / or IL1R3. More specifically, the present invention relates to methods and uses of anti-IL-1R3 antibodies in inflammatory conditions and / or diseases. Background technique [0002] Interleukin 1 receptor accessory protein (IL1RAP), also known as IL1R3, is a co-receptor for type 1 interleukin 1 receptor (IL1R1) and is indispensable for the transmission of IL-1 signaling. Once IL-1 is bound, IL-1R1 associates with IL-1RAcP to form a functional signaling receptor complex, which stimulates NFkB activity. [0003] IL-33, its receptor ST2 and IL-1RAcP also form a complex (IL-33 / ST2 / IL-1RAcP) whose activity is similar to the IL-1β / IL-1R1 / IL-1RAcP complex in terms of NFkB activation. IL-36 (IL-36α (IL-1F6), IL-36β (IL-1F8) and IL-36γ (IL-1F9)), i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P29/00C07K16/28
CPCC07K16/2866A61K2039/505C07K2317/71C07K2317/76A61P29/00C07K2317/565
Inventor S·费舍尔K·贝克曼
Owner SANOFI BIOTECH SAS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com